XOMA ROYALTY CORPORATION (XOMA) Stock Overview
USA - NASDAQ:XOMA - US98419J2069 - Common Stock
XOMA Key Statistics, Chart & Performance
The current stock price of XOMA is 37.2 USD. In the past month the price increased by 14.57%. In the past year, price increased by 34.59%.
XOMA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.07 | 394.23B | ||
| AMGN | AMGEN INC | 12.56 | 147.49B | ||
| GILD | GILEAD SCIENCES INC | 14.55 | 139.74B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.34 | 101.35B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.29 | 59.43B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.66B | ||
| ARGX | ARGENX SE - ADR | 77.57 | 44.01B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.83 | 39.57B | ||
| INSM | INSMED INC | N/A | 29.94B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.58B | ||
| NTRA | NATERA INC | N/A | 22.38B | ||
| BIIB | BIOGEN INC | 8.65 | 20.31B |
Related stock screener links
About XOMA
Company Profile
XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. The company is headquartered in Emeryville, California and currently employs 13 full-time employees. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The firm has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The firm's royalty portfolio includes OJEMDA (tovorafenib), Cetrelimab (JNJ-63723283), Ersodetug (RZ358), MIPLYFFATM (arimoclomol), Acimtamig (AFM13), Ficlatuzumab (AV-299), COM902, Vosaroxin, Aldoxorubicin, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, DSUVIA (sufentanil sublingual tablet), IXINITY, Vidutolimod (CMP-001), MT-0169, RZ-402, G03-52-0, AFM24, Mezagitamab (TAK-079), among others. The firm also acquires milestone and royalty revenue streams on late-stage or commercial assets.
Company Info
XOMA ROYALTY CORPORATION
2200 Powell Street, Suite 310
Emeryville CALIFORNIA 94608 US
CEO: James Neal
Employees: 13
Phone: 15102047239
XOMA ROYALTY CORPORATION / XOMA FAQ
What is the stock price of XOMA ROYALTY CORPORATION today?
The current stock price of XOMA is 37.2 USD. The price increased by 1.42% in the last trading session.
What is the ticker symbol for XOMA ROYALTY CORPORATION stock?
The exchange symbol of XOMA ROYALTY CORPORATION is XOMA and it is listed on the Nasdaq exchange.
On which exchange is XOMA stock listed?
XOMA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for XOMA ROYALTY CORPORATION stock?
10 analysts have analysed XOMA and the average price target is 71.06 USD. This implies a price increase of 91.02% is expected in the next year compared to the current price of 37.2. Check the XOMA ROYALTY CORPORATION stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is XOMA ROYALTY CORPORATION worth?
XOMA ROYALTY CORPORATION (XOMA) has a market capitalization of 449.75M USD. This makes XOMA a Small Cap stock.
How many employees does XOMA ROYALTY CORPORATION have?
XOMA ROYALTY CORPORATION (XOMA) currently has 13 employees.
What are the support and resistance levels for XOMA ROYALTY CORPORATION (XOMA) stock?
XOMA ROYALTY CORPORATION (XOMA) has a support level at 36.92 and a resistance level at 37.43. Check the full technical report for a detailed analysis of XOMA support and resistance levels.
Is XOMA ROYALTY CORPORATION (XOMA) expected to grow?
The Revenue of XOMA ROYALTY CORPORATION (XOMA) is expected to grow by 85% in the next year. Check the estimates tab for more information on the XOMA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy XOMA ROYALTY CORPORATION (XOMA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of XOMA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of XOMA, evaluating the profitability, health, valuation and growth aspects
- XOMA ROYALTY CORPORATION (XOMA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- XOMA ROYALTY CORPORATION (XOMA) Sales and EPS estimates to see what analysts future expectations are.
- XOMA ROYALTY CORPORATION (XOMA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- XOMA ROYALTY CORPORATION (XOMA) Insider and Institutional Ownership to learn about the owners and their transactions.
- XOMA ROYALTY CORPORATION (XOMA) Stock Chart to make your own analysis
- XOMA ROYALTY CORPORATION (XOMA) Latest news and press-releases to stay up to date.
Does XOMA ROYALTY CORPORATION (XOMA) stock pay dividends?
XOMA does not pay a dividend.
When does XOMA ROYALTY CORPORATION (XOMA) report earnings?
XOMA ROYALTY CORPORATION (XOMA) will report earnings on 2025-11-05.
What is the Price/Earnings (PE) ratio of XOMA ROYALTY CORPORATION (XOMA)?
XOMA ROYALTY CORPORATION (XOMA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.54).
What is the Short Interest ratio of XOMA ROYALTY CORPORATION (XOMA) stock?
The outstanding short interest for XOMA ROYALTY CORPORATION (XOMA) is 2.22% of its float. Check the ownership tab for more information on the XOMA short interest.
XOMA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to XOMA. When comparing the yearly performance of all stocks, XOMA is one of the better performing stocks in the market, outperforming 88.59% of all stocks.
XOMA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to XOMA. While XOMA is still in line with the averages on profitability rating, there are concerns on its financial health.
XOMA Financial Highlights
Over the last trailing twelve months XOMA reported a non-GAAP Earnings per Share(EPS) of -1.54. The EPS decreased by -38.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -7.93% | ||
| ROE | -19.17% | ||
| Debt/Equity | 1.11 |
XOMA Forecast & Estimates
10 analysts have analysed XOMA and the average price target is 71.06 USD. This implies a price increase of 91.02% is expected in the next year compared to the current price of 37.2.
For the next year, analysts expect an EPS growth of 126.86% and a revenue growth 85% for XOMA